Publications

Preclinical
November 7, 2025
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
View Publication
Preclinical
SITC
November 7, 2025
High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Church et al.
View Publication
Clinical, ZW191
AACR-EORTC-NCI
October 23, 2025
Preliminary Results From a Phase 1 First-in-Human Multicenter Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors
LoRusso et al.
View Publication
Preclinical, ZW1528
ERS
September 30, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Hardman et al.
View Publication
Preclinical, ZW1528
World Bispecific Summit
September 10 - September 10, 2025
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Alexey Berezhnoy, PhD
View Publication
Preclinical
Immuno-Oncology Summit
August 11, 2025
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
View Publication
Preclinical
T cell Engager Summit
June 26, 2025
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
View Publication
Clinical, ZW191
ESMO Gynaecological Cancers Congress
June 19, 2025
Design of a First-in-Human Multicentre Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate Utilising a Novel TOPOIi Payload, in Participants With Advanced Solid Tumours: ZWI-ZW191-101
Sommerhalder et al.
View Publication
Clinical, ZW171
ASCO
June 2, 2025
Design of a First-in-Human Multicenter Open-Label Study of ZW171, a Mesothelin x CD3–Targeting Bispecific T Cell Engager, in Participants With Advanced Solid Tumors: ZWI-ZW171-101
Johnson et al.
View Publication
Preclinical, ZW1528
ATS
May 19, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
View Publication
Preclinical
Festival of Biologics
April 23, 2025
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-Stimulation (TriTCE Co-Stim) to Improve Treatment Responses in Oncology
Chayne Piscitelli
View Publication
Preclinical
AACR
April 30, 2025
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Lau et al.
View Publication